TLP
TVTX icon

Tri Locum Partners’s Travere Therapeutics TVTX Stock Holding History

Tri Locum Partners’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-251,702
Closed -$2.25M – 55
2023
Q3 		$2.25M Buy
+251,702
New +$3.55M 0.72% 33
2022
Q3 		– Sell
-162,014
Closed -$3.93M – 61
2022
Q2 		$3.93M Buy
+162,014
New +$4.07M 1.61% 21

Other funds holding TVTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Tri Locum Partners's TVTX Position: Q4 2023 in Review

Tri Locum Partners sold out of Travere Therapeutics (TVTX) in Q4 2023, closing a stake of 251,702 shares — an estimated $2.25M sold.

Tri Locum Partners first reported a position in TVTX in Q2 2022 and held it in 2 quarters. The position peaked at $3.93M in Q2 2022. 165 funds tracked by Wall St. Rank hold TVTX as of Q4 2023.

  • Tri Locum Partners reported no remaining Travere Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Tri Locum Partners sold 251,702 Travere Therapeutics shares in Q4 2023, an estimated $2.25M.
  • Tri Locum Partners first reported a position in Travere Therapeutics in Q2 2022 and held it in 2 quarters.
  • Tri Locum Partners's Travere Therapeutics position peaked at $3.93M in Q2 2022.
  • 165 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2023.

Based on Tri Locum Partners's 13F filing for Q4 2023, filed 14 Feb 2024.